SHANGHAI MEIZER PHARMACEUTICALS CO LTD has a total of 16 patent applications. Its first patent ever was published in 2018. It filed its patents most often in WIPO (World Intellectual Property Organization), China and United States. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are JENKEN BIOSCIENCES INC, ABBOTT HEALTHCARE PRODUCTS BV and VERNALIS R & D LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 7 | |
#2 | China | 5 | |
#3 | United States | 3 | |
#4 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Shu Yongzhi | 16 |
#2 | Lin Jun | 2 |
#3 | Luo Fengjun | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020177657A1 | Chemical compound having btk-degrading activity | |
WO2021012659A1 | Compound with androgen receptor degradation activity | |
CN109952304A | One kind inhibits and the compound for the CDK that degrades | |
CN109963853A | One kind has the degradation active compound of tyrosine protein kinase JAK3 | |
WO2019042444A1 | Compound for inhibiting and degrading tyrosine protein kinase alk | |
WO2019042445A1 | Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity | |
CN109937203A | One kind has inhibition and the active compound of tyrosine protein kinase JAK1 or JAK2 of degrading |